沙库巴曲缬沙坦在急性前壁心肌梗死后心室重构中的作用  

The role of Sacubitril/Valsartan in ventricular remodeling after acute anterior myocardial infarction

作　　者：叶素伶 王莉莉[1] 谢雯丽[1] YE Su-ling;WANG Li-li;XIE Wen-li(Department of Cardiology,The Second Hospital of Dalian Medical University,116023 Dalian,China)

机构地区：[1]大连医科大学附属第二医院心内科,辽宁省大连市116023

出　　处：《中国心血管病研究》2021年第7期667-672,共6页Chinese Journal of Cardiovascular Research

摘　　要：急性前壁心肌梗死是由于左冠状动脉前降支供血中断或急剧减少导致血流动力学改变、炎症反应和肾素-血管紧张素-醛固酮系统(RAAS)及神经内分泌系统(SNS)的过度激活,最终引起心室重构,继而发生心力衰竭,不仅病死率极高,还严重影响患者的预后及生活质量。近几年来RAAS和利钠肽(NP)系统的激活越来越引起人们重视,而沙库巴曲缬沙坦(ARNI)在治疗心力衰竭、预防心室重构和高血压病等领域取得重要进展,但对于急性前壁心肌梗死,尚无明确证据表明早期应用ARNI后可以获益,本文对相关研究进行综述。Acute anterior myocardial infarction is due to the interruption or sharp reduction of blood supply to the left anterior descending artery, which leads to hemodynamic changes, inflammation and excessive activation of renin-angiotensin-aldosterone system(RAAS) and neuroendocrine system(SNS). It eventually cause ventricular remodeling, and then heart failure, which not only has a high mortality rate but also seriously affects the patient’s prognosis and quality of life. In recent years, the activation of the RAAS system and the natriuretic peptide(NP) system has attracted more and more attention, and sacubitril/valsartan(ARNI) has achieved important results in the treatment of heart failure, prevention of ventricular remodeling, and hypertension. However, in acute anterior myocardial infarction, there is no clear evidence that early use of ARNI can benefit. This article reviews related studies.

关 键 词：沙库巴曲缬沙坦 急性前壁心肌梗死 心室重构 

分 类 号：R542.22[医药卫生—心血管疾病]